TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9886900
Drug: Pulse Wave
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse Wave Analysis (PWA) for measuring Augmentation Index (AIx)
Study: 23223772
Drug: Automated administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated administration of propofol and remifentanil
Study: 21810630
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg daily dose)
Study: 28543183
Drug: YH4808 (≥200
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (≥200 mg/d)
Study: 28543183
Drug: YH4808 (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 (twice-daily regimen)
Study: 23261366
Drug: Imunoglukan P4H®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imunoglukan P4H® syrup (with pleuran-β-glucan from Pleurotus ostreatus and vitamin C)
Study: 23261366
Drug: Imunoglukan P4H®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imunoglukan P4H® syrup
Study: 19258951
Drug: Cisplatin/paclitaxel or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/paclitaxel or carboplatin/paclitaxel (first-line chemotherapy)
Study: 15462105
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg daily for 4 weeks
Study: 11737509
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine aqueous solution (C)
Study: 9240726
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) or HRT and parathyroid hormone peptide 1-38
Study: 3717020
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous heparin to maintain the whole blood clotting time between 15 and 20 minutes, and commenced warfarin therapy within 48 hours.
Study: 3717020
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous heparin and warfarin therapy if the peak creatine kinase level was more than 1,000 U/liter.
Study: 27560668
Drug: Internal conus
Normalized name: Blitum bonus-henricus pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal conus design implants (ICI)
Study: 27560668
Drug: External hex
Approvals — FDA: no, EMA: no, PMDA: no
Description: External hex design implants (EXI)
Study: 27560668
Drug: Both ICI
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ICI and EXI implants
Study: 24354839
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message reminders (5 weekly messages and 2 appointment reminders)
Study: 18380893
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and docetaxel (ddAT) chemotherapy with tamoxifen
Study: 18380893
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and docetaxel (ddAT) chemotherapy without tamoxifen
Study: 10713563
Drug: PEO/PBT 70/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEO/PBT 70/30 (degradable implants)
Study: 6361759
Drug: Chronic 4L
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic 4L plasma exchange therapy with albumin replacement
Study: 6361759
Drug: Chronic 4L
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic 4L plasma exchange therapy with plasma replacement
Study: 6361759
Drug: Chronic 4L
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic 4L plasma exchange therapy
Study: 26662838
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/ml (Gla‐300)
Study: 26662838
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/ml (Gla‐100)
Study: 24956862
Drug: Detoxifying and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detoxifying and blood circulation activating treatment with extraction of polygonum cuspidatum and hawthorn, 1 pill po, bid (5.33 mg x kg(‐1) x d(‐1) polygonum cuspidatum extraction, 5.0 mg x kg(‐1) x d(‐1) hawthorn extraction)
Study: 24956862
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg po, qd (0.33 mg x kg(‐1) x d(‐1))
Study: 22326943
Drug: L-theanine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (100 mg)
Study: 22326943
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caffeine and L-theanine
Study: 17030353
Drug: Platinum-based combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based combination chemotherapy
Study: 12092010
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens for gestational trophoblastic neoplasia
Study: 19744533
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to pictures of fruits and vegetables (reading a picture book daily for two weeks)
Study: 17550998
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone supplementation (100 mg im every 2 weeks for 26 weeks)
Study: 11401641
Drug: latanoprost (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost (50 microg/ml once daily)
Study: 29282768
Drug: Paracetamol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (3 g/day)
Study: 29282768
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (max. 10 μg/h/7 days)
Study: 27572001
Drug: Prolonged dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dual antiplatelet therapy (DAPT) for 24 months
Study: 27572001
Drug: Short dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short dual antiplatelet therapy (DAPT) for ≤6 months
Study: 18375893
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel 80 mg/m2
Study: 18375893
Drug: Every-3-weeks paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every-3-weeks paclitaxel 175 mg/m2
Study: 16361020
Drug: Standard swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard swallowing therapy
Study: 12873289
Drug: Soluble human
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble human insulin (HI)
Study: 11077352
Drug: Ciprofloxacin 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 0.2% solution (CIP)
Study: 11077352
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of polymyxin B, neomycin, and hydrocortisone suspension (PNH)
Study: 8808861
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg as needed, 12 to 24 hours before sexual activity)
Study: 8808861
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg as needed)
Study: 1442579
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg once daily
Study: 7031208
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily injections of mixed insulin
Study: 7031208
Drug: Single-dose insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose insulin regimen
Study: 30795775
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination containing Bifidobacterium longum BB536 and red yeast rice extract (10 mg/day monacolin K)
Study: 29106031
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of valsartan/amlodipine (80/5 mg)
Study: 23414938
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg daily
Study: 21989290
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination with three doses of HepB (CHO) vaccine (20μg each) administered at zero, one, and six months.
Study: 21989290
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (anti-HBs < 0.1 mIU/mL)
Study: 14737878
Drug: Capsaicin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (5 mg/mL, 30 microL applied topically)
Study: 7485814
Drug: Drug (Placebo)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (Placebo) Consumption
Study: 1791769
Drug: Once-weekly (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly (17 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Study: 1791769
Drug: Twice-weekly (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly (34 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Study: 1791769
Drug: Two years
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two years of twice-weekly treatment (9 women)
Study: 7199806
Drug: Not using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not using oral contraceptives (Control)
Study: 30043065
Drug: Escitalopram (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (5, 10, 15, or 20 mg/d)
Study: 26731792
Drug: Riboflavin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (200 mg)
Study: 26731792
Drug: Beetroot (880
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot (880 mg)
Study: 20889235
Drug: 20% to
Normalized name: GLYCERIN 20% TOP GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% to 30% salicylic acid peels every 2 weeks for a total of 4 peels along with 4% hydroquinone cream to both sides of the face twice daily
Study: 20889235
Drug: 4% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone cream to both sides of the face twice daily
Study: 15987917
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a monotherapy
Study: 12814993
Drug: High urinary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High urinary phytoestrogen excretion
Study: 12814993
Drug: High urinary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High urinary isoflavonoids excretion
Study: 12814993
Drug: Increasing excretion
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing excretion rate of mammalian lignans
Study: 10585039
Drug: Milrinone treatment
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone treatment (0.5 microg x kg(‐1) x min(‐1) for 24 hours)
Study: 10585039
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no milrinone treatment)
Study: 10585039
Drug: Milrinone treatment
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone treatment
Study: 8708685
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (mean dose 133.2 units Dysport)
Study: 1708046
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg twice a day)
Study: 6753091
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (Bdp)
Study: 23711618
Drug: Intramuscular IFNβ-1a
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular IFNβ-1a (30 μg once a week)
Study: 23711618
Drug: Subcutaneous IFNβ-1b
Normalized name: IFN-gamma 1b
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous IFNβ-1b (250 μg every other day)
Study: 11532838
Drug: Recurrent victimisation
Normalized name: Acacia decurrens extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recurrent victimisation in year 8 (reported once or twice)
Study: 31648374
Drug: Paracetamol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 0.5 g + ibuprofen 200 mg
Study: 31648374
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and ibuprofen (combined)
Study: 27177997
Drug: IFNB‐1b 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNB‐1b 500 µg
Study: 27177997
Drug: IFNB‐1b 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNB‐1b 250 µg
Study: 27177997
Drug: GA 20
Normalized name: Potiga 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA 20 mg QD
Study: 18448227
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B 30 toothbrush
Study: 14523532
Drug: Oxymetazoline without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline without preservative (Nasivin sanft 0.05% spray)
Study: 11789002
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment in patients with baseline dyslipidaemia
Study: 9364291
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg, orally once daily for 3 days)
Study: 9364291
Drug: Co-amoxiclav (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (10 mg/kg in a 4:1 ratio, orally three times daily for 5-10 days)
Study: 1539845
Drug: Droperidol 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.075 mg/kg
Study: 1539845
Drug: Metoclopramide 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.15 mg/kg
Study: 23870606
Drug: Fluticasone/formoterol (100/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol (100/10 µg BID)
Study: 23870606
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 µg BID)
Study: 23870606
Drug: Formoterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (10 µg BID)
Study: 21655065
Drug: OAL (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAL (omeprazole, amoxicillin, levofloxacin)
Study: 21655065
Drug: OAL-R (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAL-R (omeprazole, amoxicillin, levofloxacin, rifaximin)
Study: 15225153
Drug: Standard antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressant medication
Study: 1955900
Drug: Repeated toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated toxin injections
Study: 25958474
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with a 637 nm GaAlAs laser, 40 mW, continuous wave, 6.26 J/cm2 per implant, applied daily for 7 days post-surgery
Study: 23307315
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg BD for three cycles
Study: 23307315
Drug: Aerial parts
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerial parts of wood betony (AWB) 5 g TDS for three months
Study: 22238738
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of 6% triphala mouthwash
Study: 22238738
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of 0.2% chlorhexidine (active control)
Study: 18991979
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) supplementation (500 mg/day)
Study: 15009104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcipotriol ointment once daily and betamethasone dipropionate ointment once daily
Study: 15009104
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate monotherapy
Study: 9542675
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 200 mg twice daily for 7 days, followed by placebo for 7 days (n = 153)
Study: 9542675
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the morning and oral terbinafine 250 mg in the evening for 14 days (n = 151)
Study: 8117224
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg oral dose)
Study: 3403825
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dipyridamole-echocardiography test (0.84 mg/kg body weight over 10 min)
Study: 29360920
Drug: Doxycycline +
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline + Vitamin K1 cream
Study: 25604761
Drug: Long-lasting insecticidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-lasting insecticidal net screens (LLIS) with targeted treatment (TT) of breeding sites
Study: 23754384
Drug: Postextinction administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postextinction administration of L-dopa
Study: 19261278
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin treatment starting from the first day of controlled ovarian hyperstimulation in 1503 cycles
Study: 19261278
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in the remaining 922 cycles
Study: 19205092
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg and Valsartan 160 mg
Study: 19205092
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg and Felodipine 5 mg
Study: 17011843
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone and diclofenac (verum)
Study: 9596422
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of flumazenil at 0.5 mg/h for 5 hours (CI group)
Study: 8165850
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of Vi-Liq (27 to 34 months after primary immunization)
Study: 26021722
Drug: Low-dose capecitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capecitabine (1,000 mg/m² twice daily on days 1 to 14 of every 21 days)
Study: 26021722
Drug: Approved-dose capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Approved-dose capecitabine (1,250 mg/m² twice daily on days 1 to 14 of every 21 days)
Study: 15380916
Drug: Glutamine enriched
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine enriched total parenteral nutrition
Study: 15380916
Drug: Isonitrogenous control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonitrogenous control solution
Study: 11449622
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with ifosfamide 1.6 g/m2 (d 1-3) and carboplatin (AUC 4, d1) every three weeks, with 21 patients receiving amifostine 740 mg/m2 d1-3 followed by standard radiation therapy (50.4 Gy percutaneous and high-dose-rate-after-loading for 21 patients, 2 x 5 Gy).
Study: 11449622
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with ifosfamide and carboplatin.
Study: 7657052
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose tolerance test (25 g glucose/4 min)
Study: 28080126
Drug: College course
Approvals — FDA: no, EMA: no, PMDA: no
Description: College course on terrorism (treatment)
Study: 28080126
Drug: Treatment classes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment classes from universities across the United States (Study 2)
Study: 22591260
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser gingivectomy (940‐nm diode laser, ezlase, Biolase Technology Inc) as an adjunct to nonsurgical periodontal treatment
Study: 22591260
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment only
Study: 20032535
Drug: Novel antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel antiviral agents
Study: 15035683
Drug: Soya milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya milk (0.44 mg isoflavones/kg body weight)
Study: 15035683
Drug: Tempeh (0.44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tempeh (0.44 mg isoflavones/kg body weight)
Study: 15035683
Drug: Textured vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured vegetable protein (TVP) (0.44 mg isoflavones/kg body weight)
Study: 9551030
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription by specialists
Study: 9551030
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription by general practitioners
Study: 9551030
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription for elderly females by specialists